Atossa Therapeutics (NASDAQ:ATOS) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Atossa Therapeutics (NASDAQ:ATOS) released its quarterly earnings data on Tuesday. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01, Zacks reports.

Atossa Therapeutics Trading Down 3.3 %

Atossa Therapeutics stock opened at $0.72 on Wednesday. The stock has a 50-day moving average price of $0.80 and a 200 day moving average price of $1.11. Atossa Therapeutics has a 52 week low of $0.66 and a 52 week high of $2.31. The stock has a market cap of $91.05 million, a PE ratio of -3.29 and a beta of 1.20.

Wall Street Analyst Weigh In

ATOS has been the subject of a number of research reports. Ascendiant Capital Markets lifted their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Atossa Therapeutics in a research note on Wednesday.

Institutional Investors Weigh In On Atossa Therapeutics

An institutional investor recently raised its position in Atossa Therapeutics stock. Bank of America Corp DE lifted its position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 111,475 shares of the company’s stock after buying an additional 37,809 shares during the period. Bank of America Corp DE owned 0.09% of Atossa Therapeutics worth $105,000 as of its most recent SEC filing. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.